The company’s lead antiviral product is the ACE2-antivirus, a novel multivalent neutralizing therapeutic targeting all SARS coronaviruses utilizing ACE2 as a cell-entry receptor (Fig.

When the SARS-CoV-2 virus enters the human body, it breaks into cells with the help of two proteins that it finds there, ACE2 and TMPRSS2. While there has been much discussion of viral infection in ...